# Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

> **NCT00666263** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 50 (actual)

## Conditions studied

- Multifocal Motor Neuropathy

## Interventions

- **BIOLOGICAL:** Immune Globulin Intravenous (human), 10%
- **BIOLOGICAL:** 0.25% human albumin solution (Placebo)

## Key facts

- **NCT ID:** NCT00666263
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-22
- **Primary completion:** 2011-08-11
- **Final completion:** 2011-08-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00666263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00666263, "Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00666263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*